Skip to content

OnKure Therapeutics, Inc. OKUR Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$58.75M+0.5%-$59.52M-13.0%-$63.46M-$60.31M-$59.06M
$433K-6.5%$447K-2.6%$459K-27.6%$465K-17.4%$463K-5.5%
$11.67M+62.8%$11.63M+157%$11.15M$8.26M$7.17M
-$50.76M+6.8%-$51.83M-1.4%-$63.67M-$61.29M-$54.49M
$33K-45.9%$46K-11.5%$52K-40.2%$64K-27.3%$61K-26.5%
-$33K-100%-$46K-100%$15.87M$15.86M$15.86M
$116.04M
$95.45M+23.3%-$51.71M-164%$62.37M+1,254%$64.74M+261%$77.41M+2,902%
-$50.79M+6.9%-$51.87M-1.4%-$63.72M-$61.36M-$54.55M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does OnKure Therapeutics, Inc. generate?
OnKure Therapeutics, Inc. (OKUR) generated -$50.8M in operating cash flow over the trailing twelve months.
What is OnKure Therapeutics, Inc.'s free cash flow?
After $33.0K of capital expenditures, OnKure Therapeutics, Inc.'s free cash flow was -$50.8M over the trailing twelve months, up 6.9% year over year.
Where does OnKure Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from OnKure Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.